BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17640598)

  • 1. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation.
    Nachbaur D; Schumacher P; Auberger J; Clausen J; Kircher B
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):942-7. PubMed ID: 17640598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
    Min CK; Kim SY; Lee MJ; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Cho CS
    Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.
    Kim DH; Lee NY; Lee MH; Sohn SK
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1408-16. PubMed ID: 19041064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interleukin-6 and vascular endothelial growth factor in hematopoietic stem cell transplantation.
    Azarpira N; Dehghani M; Darai M
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):521-5. PubMed ID: 22569438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of insulin-like growth factor after stem cell transplantation.
    Munker R; Salat C; Pihusch R; Diem H; Hiller E; Glass J; Kolb HJ; Yu H
    Eur J Med Res; 2001 Apr; 6(4):181-4. PubMed ID: 11309231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival.
    Norlin AC; Sairafi D; Mattsson J; Ljungman P; Ringdén O; Remberger M
    Bone Marrow Transplant; 2008 Feb; 41(3):267-73. PubMed ID: 17994123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients.
    Pihusch V; Rank A; Steber R; Pihusch M; Pihusch R; Toth B; Hiller E; Kolb HJ
    Transplantation; 2006 May; 81(10):1405-9. PubMed ID: 16732177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Moiseev IS; Lapin SV; Surkova EA; Lerner MY; Vavilov VN; Afanasyev BV
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1677-82. PubMed ID: 24035780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of acute liver "graft-versus-host disease" following allogeneic myeloablative stem cell transplant].
    Doki N; Saito Y; Hatsumi N; Irisawa H; Sakura T; Miyawaki S
    Rinsho Ketsueki; 2004 Jan; 45(1):57-60. PubMed ID: 14999935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation.
    Najima Y; Ohashi K; Miyazawa M; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
    Am J Hematol; 2009 May; 84(5):298-301. PubMed ID: 19338041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.